Osteopore Boosts Revenue 10% with New Asia Pacific Partnerships

• Revenue up 10% QoQ and 4% YoY to AUD 754K
• New distribution partners in China, Latin America, and Hong Kong
• 3D printing services launched as additional revenue stream
• Secured autologous dentin bone graft and injectable bone filler rights
• Collaborations with Singapore hospitals for product innovation

Revenue Growth Fueled by Strategic Partnerships

Osteopore Limited (ASX:OSX) recorded AUD 754,000 in revenue for Q1 CY26, marking a 10% increase from the previous quarter and a 4% rise year-on-year. This steady growth reflects the company’s expanding footprint in key international markets, with new distribution agreements signed with Essex-Bio (Majeton) in China, Medprin in Latin America, and MontsMed in Hong Kong. These partnerships broaden Osteopore’s access to high-potential regions, notably increasing its reach from a single country to entire regions such as Latin America’s 20 countries.

Notably, the collaboration with Majeton, valued above RMB 12 million (approximately AUD 2.5 million), targets the Chinese dental, orthodontic, and maxillofacial markets, leveraging Essex Bio-Technology’s robust financial standing. This deal replaces prior arrangements with CellHeal, streamlining Osteopore’s commercialisation efforts in Greater China.

Osteopore’s expansion into Latin America via Medprin, a subsidiary of a Shenzhen-listed neurosurgery firm with a market cap near AUD 1 billion, is expected to significantly enhance regional distribution, while the Hong Kong deal with MontsMed focuses on orthopaedic trauma reconstruction, a key segment for Osteopore’s devices. Hong Kong’s strategic position as a gateway to the Greater Bay Area offers regulatory and innovation advantages that may accelerate adoption.

Diversification Through 3D Printing and Bone Graft Technologies

In addition to product distribution, Osteopore has launched a 3D printing services business, providing pre-surgical planning models and sterilised intra-operative cutting jigs. This move taps into the rapidly growing global healthcare 3D printing market, forecasted to reach USD 8 billion by the early 2030s, with Asia-Pacific among the fastest-growing regions.

The company also secured distribution rights in Singapore for an autologous dentin bone graft technology that converts extracted teeth into osteoinductive dentin grafts within minutes. This innovation targets the Asia Pacific dental bone graft market, projected to reach AUD 425 million by 2030. Complementing this, Osteopore obtained non-exclusive rights for an injectable regenerative bone filler across Southeast Asia, addressing a market segment estimated between AUD 94.6 million and AUD 284 million and benefiting from rising healthcare spending and surgical capacity in countries like Singapore and Malaysia.

Innovation Collaborations Strengthen Product Pipeline

Osteopore is advancing product innovation through collaborations with Singapore’s Tan Tock Seng Hospital and National University Hospital. The partnership with Tan Tock Seng focuses on developing an implant for avascular necrosis of the hip, a condition affecting thousands annually in the U.S., while the collaboration with National University Hospital aims to create a precision catheter guide to improve outcomes in neurosurgery. These projects illustrate Osteopore’s commitment to expanding its regenerative and surgical device portfolio.

Further strengthening its pipeline, Osteopore in-licensed a bone and tissue regeneration technology from Accelerate Technologies Pte Ltd, A*STAR’s technology transfer arm. This positions Osteopore to enter the bone morphogenetic protein-2 market, valued at approximately AUD 934 million in 2024 and expected to grow steadily.

Financial Position and Funding

Osteopore ended the quarter with a cash balance of AUD 1.734 million and net operating cash outflows of AUD 205,000, partly offset by a dossier fee of approximately AUD 565,000 received from Majeton as part of their commercialisation agreement. The company retains access to a AUD 20 million redeemable convertible note facility, with AUD 5.75 million drawn as of 31 March 2026, providing substantial funding runway.

Related party payments, including director fees and salaries, amounted to AUD 190,000 during the quarter. The company’s financial strategy includes measured drawdowns on convertible notes, as demonstrated by recent incremental funding activity supporting ongoing operations and growth initiatives.

Scaling Operations with Asia Pacific Centre of Excellence

To support its commercial and innovation ambitions, Osteopore plans to establish its first Asia Pacific Global Centre of Excellence in Hong Kong. This facility aims to replicate the successful Singapore model, enabling co-development, testing, and scaling of customised medical devices. The centre is expected to deepen collaborations with local clinicians and accelerate product adoption across the region.

Osteopore’s multi-faceted approach, combining revenue growth, strategic partnerships, technological innovation, and regional infrastructure development, positions it to capture expanding opportunities in the Asia Pacific regenerative medicine and orthobiologics markets. The company’s recent moves build on its earlier capital management efforts, including the further $250,000 drawdown on convertible notes and the injectable bone filler distribution deal(b8762b51-10ae-4f37-a7a4-c5219bfa257bfa), highlighting a clear focus on growth and diversification.

Bottom Line?

Osteopore’s expanding partnerships and innovation pipeline signal steady progress, but the impact of new products on revenue remains to be seen amid ongoing funding draws.

Questions in the middle?

• How soon will new distribution agreements translate into meaningful revenue gains?
• What regulatory hurdles might affect product launches in China and Hong Kong?
• How will Osteopore balance ongoing R&D investments with cash flow sustainability?